BBIO vs. CLS
BBIO (BridgeBio Pharma, Inc.) and CLS (Celestica Inc.) are both stocks. BBIO operates in Biotechnology (Healthcare), while CLS operates in Electronic Components (Technology). Over the past 5 years, BBIO returned 1.89%/yr vs 114.81%/yr for CLS. At a 0.24 correlation, their price movements are largely independent.
Performance
BBIO vs. CLS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBIO achieves a -11.92% return, which is significantly lower than CLS's 30.75% return.
BBIO
- 1D
- -0.35%
- 1M
- -0.03%
- YTD
- -11.92%
- 6M
- -9.25%
- 1Y
- 74.44%
- 3Y*
- 61.48%
- 5Y*
- 1.89%
- 10Y*
- —
CLS
- 1D
- 3.98%
- 1M
- 2.92%
- YTD
- 30.75%
- 6M
- 13.42%
- 1Y
- 220.14%
- 3Y*
- 209.55%
- 5Y*
- 114.81%
- 10Y*
- 43.16%
BBIO vs. CLS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | -11.92% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 27.22% |
CLS Celestica Inc. | 30.75% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | 21.98% |
Correlation
The correlation between BBIO and CLS is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019 | 0.24 |
Fundamentals
BBIO:
$13.12B
CLS:
$44.72B
BBIO:
-$3.76
CLS:
$8.28
BBIO:
23.00
CLS:
3.24
BBIO:
$566.04M
CLS:
$13.81B
BBIO:
$538.20M
CLS:
$1.60B
BBIO:
-$602.24M
CLS:
$1.32B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBIO vs. CLS — Risk / Return Rank
BBIO
CLS
BBIO vs. CLS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BBIO | CLS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.46 | ||
| Sortino ratioReturn per unit of downside risk | -0.68 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.39 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 3.70 | 7.58 | -3.88 |
| Martin ratioReturn relative to average drawdown | 9.25 | 18.88 | -9.63 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BBIO | CLS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.60 | 3.06 | -1.46 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.02 | 2.01 | -1.98 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.87 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.16 | 0.27 | -0.11 |
Drawdowns
BBIO vs. CLS - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, roughly equal to the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for BBIO and CLS.
Loading charts...
Drawdown Indicators
| BBIO | CLS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -96.93% | +4.13% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -29.24% | +8.99% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -53.96% | +4.88% |
Max Drawdown (5Y)Largest decline over 5 years | -91.89% | -53.96% | -37.93% |
Max Drawdown (10Y)Largest decline over 10 years | — | -80.60% | — |
Current DrawdownCurrent decline from peak | -15.69% | -18.18% | +2.49% |
Average DrawdownAverage peak-to-trough decline | -45.80% | -73.36% | +27.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.07% | 11.72% | -3.65% |
Volatility
BBIO vs. CLS - Volatility Comparison
The current volatility for BridgeBio Pharma, Inc. (BBIO) is 12.10%, while Celestica Inc. (CLS) has a volatility of 26.60%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBIO | CLS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.10% | 26.60% | -14.50% |
Volatility (6M)Calculated over the trailing 6-month period | 34.41% | 55.08% | -20.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.75% | 72.52% | -25.77% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.95% | 57.62% | +28.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.80% | 49.93% | +33.87% |
Dividends
BBIO vs. CLS - Dividend Comparison
Neither BBIO nor CLS has paid dividends to shareholders.
Financials
BBIO vs. CLS - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BBIO vs. CLS - Profitability Comparison
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
Frequently Asked Questions
BBIO and CLS have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (26.60%) compared to BBIO (12.10%). In terms of maximum drawdown, BBIO dropped -92.80% vs CLS's -96.93%.
CLS currently has the higher Sharpe Ratio (3.06 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBIO and CLS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer